ArticleScientific reports2026
Green spectrofluorimetric determination of Ibrexafungerp using NBD-Cl derivatization.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Ibrexafungerp (IBX) is the first approved triterpenoid antifungal indicated for the treatment of vulvovaginal candidiasis, particularly in cases resistant to azole and echinocandin therapies. In this study, a sensitive, simple, and environmentally sustainable spectrofluorimetric method was developed for the quantitative determination of IBX in pharmaceutical tablets. The method is based on chemical derivatization of IBX with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl), forming a highly fluorescent adduct measured at an emission wavelength of 554 nm following excitation at 472 nm. The reaction proceeds via nucleophilic substitution between the primary amine group of IBX and NBD-Cl. Experimental conditions affecting derivatization and fluorescence intensity were systematically optimized. The method exhibited excellent linearity over the concentration range of 150-2000 ng/mL (r² = 0.9996), with limits of detection and quantification of 39.196 and 118.774 ng/mL, respectively. Validation according to ICH guidelines confirmed satisfactory accuracy, precision, and robustness. The method was successfully applied without interference from excipients. Greenness assessment using Analytical Eco-Scale, AGREE, and GAPI tools confirmed the environmentally friendly nature of the proposed method, supporting its suitability for routine quality control applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.